Alzheimer’s disease (AD), the most prevalent neurodegenerative disease globally, poses a significant threat to human health. Most AD patients are diagnosed after the age of 65, categorized as late-onset AD (LOAD). However, about 5%–10% of AD patients show symptoms before the age of 65, exhibiting the same pathological characteristics as AD, classified as early-onset AD (EOAD).